Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
454 studies found for:    myelodysplastic syndrome | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
2 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
3 Unknown  Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis
4 Recruiting Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
5 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Secondary Myelodysplastic Syndromes
Interventions: Drug: decitabine;   Drug: azacitidine;   Drug: cytarabine;   Drug: idarubicin;   Drug: daunorubicin hydrochloride;   Procedure: quality-of-life assessment
6 Recruiting Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Other: Transient elastography
7 Recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
8 Recruiting A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Decitabine Injection
9 Not yet recruiting Efficacy and Safety Study of CC-486 (ORAL AZACITIDINE) in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: CC-486 (ORAL AZACITIDINE)
10 Recruiting Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
Conditions: Leukemia;   Myelodysplasia;   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia
Interventions: Procedure: Umbilical Cord Blood Transfusion;   Drug: Fludarabine;   Drug: Busulfan;   Drug: Melphalan
11 Recruiting APG101 in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Treatment with APG101;   Procedure: Bone marrow collection;   Procedure: Blood drawings
12 Unknown  Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Bortezomib
13 Recruiting Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Conditions: Acute Myeloid Leukemia;   Myeloproliferative Neoplasms;   Myelodysplastic Syndromes;   Myeloproliferative/Myelodysplastic Neoplasm
Interventions: Drug: Induction Chemotherapy;   Drug: Consolidation Chemotherapy;   Drug: Autologous Stem Cell Transplantation;   Drug: Allogeneic Stem Cell Transplantation;   Drug: Low Dose Cytarabine;   Drug: Decitabine
14 Recruiting Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
Conditions: Leukemia;   Myelodysplastic Syndrome
Intervention: Behavioral: Interview
15 Unknown  5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
16 Not yet recruiting Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
17 Unknown  The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality
Condition: Myelodysplastic Syndromes
Intervention: Drug: lenalidomide
18 Recruiting A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms
Conditions: Acute Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Intervention: Drug: CPI-0610
19 Not yet recruiting Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy
Condition: Myelodysplastic Syndrome
Interventions: Drug: BSC;   Drug: HIDRA/VPA
20 Recruiting Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: micafungin;   Drug: posaconazole

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years